Publications

I have contributed to numerous publications over the years. Some of my notable works include:

In 2023, I co-authored a paper on the co-administration of an effector antibody that enhances the half-life and therapeutic potential of RNA-encoded nanobodies, published in Scientific Reports.

In 2022, I was part of a team that demonstrated how phenylalanine hydroxylase mRNA can rescue the phenylketonuria phenotype in mice, published in Frontiers in Bioengineering and Biotechnology. Additionally, I contributed to research showing that mRNA-based therapy is superior to the standard-of-care for treating hereditary tyrosinemia 1 in a mouse model, published in Molecular Therapy – Methods & Clinical Development.

I also co-authored a study on a nine-strain bacterial consortium that improves portal hypertension and insulin signaling and delays NAFLD progression in vivo, published in Biomedicines.

In 2021, I was involved in research on therapeutic HNF4A mRNA attenuating liver fibrosis in a preclinical model, published in J Hepatol.

My earlier works include studies on mRNA as a novel treatment strategy for hereditary spastic paraplegia type 5 (SPG5), published in Molecular Therapy – Methods & Clinical Development in 2019, and on mRNA mediating passive vaccination against infectious agents, toxins, and tumors, published in EMBO Molecular Medicine in 2017.

  1. Thran M, Pönisch M, Danz H, Horscroft N, Ichtchenko K, Tzipori S, Shoemaker C. (2023) Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies. Scientific Reports. 2023 Sep 5;13(1):14632
  2. Cacicedo M, Weinl-Tenbruck C, Frank D, Limeres MJ, Wirsching S, Hilbert K, Pasha F, Mansure A, Horscroft N, Hennermann J, Zepp F, Chevessier-Tünnesen F, Gehring S. (2022) Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Frontiers in Bioengineering and Biotechnology. Oct; Vol 10-2022
  3. Cacicedo M, Weinl-Tenbruck C, Frank D, Wirsching S, Straub B, Hauke J, Okun J, Horscroft N, Hennermann J, Zepp F, Chevessier-Tünnesen F, Gehring S. (2022) mRNA-based Therapy Proves Superior to the Standard-of-care for Treating Hereditary Tyrosinemia 1 in a Mouse Model. Molecular Therapy – Methods & Clinical Development. 26:294-308
  4. Pinheiro I, Barberá A, Raurell I, Estrella F, de Leeuw M, Bolca S, Gottardi D, Horscroft N, Possemiers S, Teresa Salcedo M, Genescà J, Martell M, Augustin S. (2022) A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. Biomedicines. 10(5):1191.
  5. Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. (2021) Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol. Dec;75(6):1420-1433.
  6. Hauser S, Pönisch M, Schelling Y, Höflinger P, Schuster S, Teegler A, Betten R, Gustafsson J, Hübener-Schmid J, Schlake T, Chevessier-Tünnesen F, Horscroft N, Björkhem I, Schoels L. (2019) Messenger RNA as novel treatment strategy for Hereditary Spastic Paraplegia Type 5 (SPG5). Molecular Therapy – Methods & Clinical Development. 15:359-370
  7. Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui B, Hope M, Tam Y, Horscroft N, Heidenreich R, Fotin- Mleczek M, Shoemaker C, Schlake T. (2017) mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Molecular Medicine. Oct; 9(10): 1434–1447
  8. Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V. (2017) Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. Jan 3;15(1):1
  9. Flores MV, Hickling TP, Sreckovic S, Fidock M, Horscroft N, Katragada M, Savic B, Rawal J, Delpuech-Adams O, Robas N, Corey T, Nelms L, Lawton M, Mareck J, Stubbs M, Westby M, Ciaramella G. (2012). Preclinical studies of PF-04849285, an interferon alpha8 fusion protein for the treatment of HCV. Antiviral Therapy. 17(5):869-81
  10. Perkins H, Khodai T, Mechiche H, Colman P, Burden F, Laxton C, Horscroft N, Corey T, Fidock M, Rodrigues D, Rawal J, Heyen J, Westby M, Bright H. (2012) Therapy with TLR7 agonists induces lymphopenia: Correlating pharmacology to mechanism in a mouse model. J Clin Immunol. 32(5):1082-92
  11. Horscroft N, Pryde D and Bright H. (2012) Antiviral applications of Toll-like receptor agonists. J. Antimicrob. Chemother. 67(4): 789-801.
  12. Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. (2011) Discovery of a highly potent series of TLR7 agonists. Bioorganic and Med Chem Letters. 21(19):5939-43.
  13. Murray E, Burden F, Horscroft N, Smith-Burchnell C, Westby M. (2011) Knockdown of USP18 activity greatly increases IFN-2a signalling and ISG induction but does not increase antiviral activity in Huh7.5 cells. Antimicrob Agents Chemother. 55(9):4311-9.
  14. Fidock M, Souberbielle B, Laxton C, Rawal J, Adams O, Corey T, Colman P, Kumar V, Cheng J, Wright K, Srinivasin S, Rana K, Craig C, Horscroft N, Westby M, Webster R, van der Ryst E.(2011) The innate immune response, clinical outcomes and ex-vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clinical Pharmacology & Therapeutics. 89(6):821-9.
  15. Tran T, Pryde D, Adam F, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox D, Hay D, Hitchin J, Horscroft N, Howard M, Gardner I, Jones H, Jones P, Laxton C, Parkinson T, Parsons G, Proctor K, Smith M, Smith N, Thomas A. (2011) Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection. Bioorganic and Med Chem Letters. 21(8):2389-93.
  16. Pryde D, Tran T, Parsons G, Bish G, Adam F, Smith M, Hay D, Paradowski M, Proctor K, Parkinson T, Laxton C, Fox D, Horscroft N, Ciaramella G, Jones H, Duckworth J, Benson N, Harrison A, Webster R. (2011) The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection. Med Chem Commun, 2 (3), 185 – 189.
  17. Clarke S, Laxton C, Horscroft N, Richard V, Thomas A, Parkinson T. (2009) Comparison of rat and human responses to toll-like receptor 7 activations. J Interferon Cytokine Res. 29(2):113-26
  18. Thomas A, Laxton C, Rodman J, Myanger N, Horscroft N, Parkinson T. (2007) Investigating toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother. 51(8):2969-78.
  19. Horscroft N, Lai VC, Cheney W, Yao N, Wu JZ, Hong Z, Zhong W. (2005). Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother. 16(1):1-12.
  20. Horscroft N, Bellows D, Ansari I, Lai VC, Dempsey S, Liang D, Donis R, Zhong W, Hong Z. (2005). Establishment of a subgenomic replicon for bovine viral diarrhoea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. J Virol. 79(5):2788-96.
  21. Cheney IW, Naim S, Lai VC, Dempsey S, Bellows D, Walker MP, Shim JH, Horscroft N, Hong Z, Zhong W. (2002). Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virology. 297(2):298-306.
  22. Solbrig MV, Schlaberg R, Briese T, Horscroft N, Lipkin WI. (2002). Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. Antimicrob Agents Chemother. 46(7):2287-91.
  23. Hornig M, Solbrig M, Horscroft N, Weissenbock H, Lipkin WI. (2001). Borna disease virus infection of adult and neonatal rats: models for neuropsychiatric disease. Curr Top Microbiol Immunol. 253:157-77.
  24. Solbrig MV, Koob GF, Parsons LH, Kadota T, Horscroft N, Briese T, Lipkin WI. (2000). Neurotrophic factor expression after CNS viral injury produces enhanced sensitivity to psychostimulants: a potential mechanism for addiction vulnerability. J Neurosci. 20(21): RC104.
  25. Horscroft, N., and Roy, P. (2000). NTP-binding and phosphohydrolase activity associated with purified Bluetongue virus non-structural protein NS2. J Gen Virol; 81: 1961-1965
  26. Hornig, M., Weissenböck, H., Horscroft, N, Lipkin, W.I. (1999). An infection-based model for neurodevelopmental damage. PNAS 96(21):12102-12107
  27. Horscroft, N., and Roy, P. (1997). Thermal denaturation of proteins for SDS-PAGE analysis by microwave irradiation. Biotechniques 22(2):224-226.